Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Reexamination Certificate
2005-08-09
2005-08-09
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
C424S677000, C424S709000, C514S046000, C514S045000, C514S255060, C514S851000
Reexamination Certificate
active
06926911
ABSTRACT:
Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
REFERENCES:
patent: 4826679 (1989-05-01), Roy
patent: 5162348 (1992-11-01), Glass
patent: 5182299 (1993-01-01), Gullans et al.
patent: 5441938 (1995-08-01), Speert et al.
patent: 5441983 (1995-08-01), Hwang et al.
patent: 5516798 (1996-05-01), Ferket
patent: 5569450 (1996-10-01), Duan et al.
patent: 5607691 (1997-03-01), Hale et al.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5725841 (1998-03-01), Duan et al.
patent: 5817028 (1998-10-01), Anderson
patent: 5837226 (1998-11-01), Jungherr et al.
patent: 5863563 (1999-01-01), Scheele
patent: 5876700 (1999-03-01), Boucher, Jr. et al.
patent: 5880098 (1999-03-01), Häussinger
patent: WO 91/14435 (1991-10-01), None
patent: WO 97/38686 (1997-10-01), None
patent: WO 97/48679 (1997-12-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 99/61012 (1999-12-01), None
PCT Search Report for PCT/US99/30585.
Handler et al.;Kidney Cell Survival in High Tonicity, Comp. Biochem. Physiol. 117A, No. 3:301-304 (1997).
Travis et al.;Activity of Abundant Antimicrobials of the Human Airway, Am. J. of Resp. Cell and Molecular Biol. 20:872-878 (1999).
Burg,Molecular basis of osmotic regulation, Walter B, Cannon Lecturepp. F983-F996 (1995).
Communication with Supplementary Partial European Search Report, EP 99 96 8166, Aug. 4, 2003.
Aitken et al.,Analysis of Sequential Aliquots of Hypertonic Saline Solution-Induced Sputum From Clinically Stable Patients with Cystic Fibrosis, Chest, vol. 123, No. 3, Mar. 2003, pp. 792-799.
De Boeck et al.,Sputum Induction in Young Cystic Fibrosis Patients, European Respiratory Journal, vol. 16, 2000, pp. 91-94.
Eng et al.,Short-Term Efficacy of Ultrasonically Nebulized Hypertonic Saline in Cystic Fibrosis, Pediatric Pulmonology, vol. 21, 1996, pp. 77-83.
Henig et al.,Sputum Induction As a Research Tool for Sampling the Airways of Subjects With Cystic Fibrosis, Thorax, vol. 56, 2001, pp. 306-311.
Hjalmarsen et al.,Sex hormone responses in healthy men and male patients with chronic obstructive pulmonary disease during an oral glucose load, Scand. J. Clin. Lab. Invest., vol. 56, No. 7, Nov. 1996, pp. 635-640.
Knowles et al,Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis, New England Journal of Medicine, vol. 325, No. 8, Aug. 22, 1991, pp. 575-577.
McShane et al.,Airway surface pH in subjects with cystic fibrosis, Eur. Respir. J., vol. 21, 2003, pp. 37-42.
Olivier et al.,Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/− amiloride in normal human adults, Am., J. Respir. Crit. Care Med., vol. 154, No. 1, Jul. 1996, pp. 217-223.
Robinson et al.,Effect of Hypertonic Saline, Amiloride, and Cough on Mucociliary Clearance in Patients With Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol. 153, 1996, pp. 1503-1509.
Rodwell et al.,Airway Responsiveness to Hyperosmolar Saline Challenge in Cystic Fibrosis: A Pilot Study, Pediatric Pulmonology, vol. 21, 1996, pp. 282-289.
Rubin et al.,Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis, Chest, vol. 109, No. 2, Feb. 1996, 348(5), 5 pp.
Sagel et al.,Induced Sputum Inflammatory Measures Correlate With Lung Function in Children With Cystic Fibrosis, The Journal of Pediatrics, vol. 141, No. 6, Dec. 2002, pp. 811-817.
Schuller-Levis et al.,Taurine protects rat bronchioles from acute ozone-induced lung inflammation and hyperplasia, Experimental Lung Research, vol. 21, 1995, pp. 877-888.
Cropp,Effectiveness of Brochodilators in Cystic Fibrosis, The American Journal of Medicine, vol. 100, Supp. 1A, 1996, pp. 19s-29s.
Myers Bigel & Sibley & Sajovec
The University of North Carolina at Chapel Hill
Wang Shengjun
LandOfFree
Compounds and methods for the treatment of airway diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of airway diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of airway diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517160